R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
R&D Challenges and opportunities in synthetic clinical trials Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control
Digital Transitioning PROs from paper to digital: Maintaining data i... Patient-reported outcomes (PROs) provide important insights for clinical trials.
Partner Content Partner Content Integrity Matters: The Importance of Data Integrity in Pharm... Data Integrity
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
